Country-based Local Fund Agents, who monitor grant implementation and progress on behalf of the Global Fund, complete a monthly survey online to help identify potential risks and disruptions to programs. The tool is not meant to be a rigorous assessment of the country situation. The data is based on in-country stakeholder views but not on verified data. Key insights as of 1 December 2021:
Countries in lockdown: 33% of countries where the Global Fund invests are experiencing nationwide restrictions as of 1 December, remaining stable since 1 October. 15% of countries are still experiencing local restrictions that impact the programs run by the Global Fund.
Costed national plans: The share of countries with fully costed response plans in place for their COVID-19 response has remained stable since 1 November. On 1 December 2021, 84% of countries had a costed response plan in place, compared to 85% on 1 September 2021, 83% on 15 November 2020, and 75% on 15 June 2020.
Disruption to health service delivery: As of 1 December, disruption to malaria and TB service delivery has increased, while disruption to HIV service delivery has declined. 45% of countries are reporting no or low disruption to health service delivery for HIV, compared to 39% of countries for malaria and 38% of countries for TB. 3% of countries are experiencing very high disruption for malaria services, compared to 1% for TB services and 0% for HIV services.
Disruption to supply of key medicines: The risk trend for the supply of key TB medicines has sharply increased as of 1 December. The risk trend for the supply of malaria medicines slightly increased, while the risk trend for the supply of HIV medicines remains stable. For all three diseases, more than half of the countries where the Global Fund invests have a minimum 6 months’ supply capacity of key medicines. As of 1 December, 7% of countries were experiencing shortages for HIV medicines, 5% of countries were experiencing shortages for TB medicines, and 4% of countries were experiencing shortages for malaria medicines.
Lab services: As of 1 December, 49% of countries are reporting no or low HIV and/or TB lab services disruption, up from 48% on 1 November. 44% of countries are reporting moderate disruption, a slight improvement since 1 November. The percentage of countries experiencing high HIV and/or TB lab services disruption has slightly increased from 2% on 1 November to 3% on 1 December, while the share of countries reporting very high disruption has decreased to 1%.